Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 21 |
| Active Pipeline (Recruiting Now) | 12 (11) |
| Completed vs Stopped Early | 9 / 0 (0.0%) |
| Median Closed Actual Enrollment | 480 participants |
| Physical Hospital Site Disclosure | 56.5% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Northwest Clinical Research Center | Bellevue, WA | 7 |
| Advanced Research Center, Inc. | Anaheim, CA | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06229210 | Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder | Phase III | RECRUITING |
| NCT06372964 | Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients | Phase III | RECRUITING |
| NCT06690398 | Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients | Phase III | RECRUITING |
| NCT05850689 | Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Phase III | RECRUITING |
| NCT06706674 | Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Intra-Cellular Therapies Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.